MedWatch

Italian hearing aid retailer expects first OTC products in 2022

In the second half of next year, Amplifon expects to see the first over-the-counter products on the US market.

Photo: JOHN GRESS/REUTERS / X01637

Amplifon, a large Italian retailer of hearing aids, is expecting its first marketed products to be sold without a prescription in the US during the second half of 2022, the company revealed during its capital markets day on Monday.

The hearing healthcare company's expectation is that the proposed regulations on the OTC market, which would enable over-the-counter sales of hearing aids to adults with mild to moderate hearing loss – sidestepping an appointment with an audiologist – willl be presented by the US Food and Drug Administration (FDA) in November.

Hereafter, there will be a short window for industry objections and recommendations, before approximately six months of implementation commence.

The timeline therefore fits with the executive order that President Joe Biden signed at the beginning of July, which sent ripples through the hearing aid market.

In the order, Biden criticized the prices of hearing aids, which he thinks have become too expensive for US families. He therefore directed the FDA to propose rules for the over-the-counter sales of hearing aids within 120 days.

Italian hearing aid retailer disappoints with growth prognosis

New GN device to open giant market for mild hearing loss 

Hearing industry challenger applauds Biden's price battle

New Biden order criticizing hearing aid expense causes falling share prices 

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs